Neurocrine Biosciences
Market Cap
US$9.6b
Last Updated
2020/01/20 23:42 UTC
Data Sources
Company Financials +
Executive Summary
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States.
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential with proven track record.
Similar Companies
Share Price & News
How has Neurocrine Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NBIX has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
1.6%
NBIX
1.2%
US Biotechs
1.2%
US Market
1 Year Return
14.4%
NBIX
12.4%
US Biotechs
24.2%
US Market
Return vs Industry: NBIX exceeded the US Biotechs industry which returned 10.9% over the past year.
Return vs Market: NBIX underperformed the US Market which returned 24.7% over the past year.
Shareholder returns
| NBIX | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.6% | 1.2% | 1.2% |
| 30 Day | -4.7% | 0.2% | 3.5% |
| 90 Day | 6.7% | 17.5% | 11.7% |
| 1 Year | 14.4%14.4% | 13.4%12.4% | 26.9%24.2% |
| 3 Year | 169.5%169.5% | 30.1%25.8% | 53.0%43.2% |
| 5 Year | 212.0%212.0% | 2.6%-2.3% | 75.3%56.0% |
Price Volatility Vs. Market
How volatile is Neurocrine Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
17 hours ago | Simply Wall St
How Should Investors Feel About Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay?2 weeks ago | Simply Wall St
Here's Why Neurocrine Biosciences's (NASDAQ:NBIX) Statutory Earnings Are Arguably Too Conservative1 month ago | Simply Wall St
An Intrinsic Calculation For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Suggests It's 31% UndervaluedValuation
Is Neurocrine Biosciences undervalued compared to its fair value and its price relative to the market?
45.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NBIX ($107.84) is trading below our estimate of fair value ($193.3)
Significantly Below Fair Value: NBIX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NBIX is poor value based on its PE Ratio (466.7x) compared to the Biotechs industry average (20.1x).
PE vs Market: NBIX is poor value based on its PE Ratio (466.7x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: NBIX is poor value based on its PEG Ratio (12.5x)
Price to Book Ratio
PB vs Industry: NBIX is overvalued based on its PB Ratio (17.3x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is Neurocrine Biosciences forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
37.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NBIX's forecast earnings growth (37.3% per year) is above the savings rate (1.7%).
Earnings vs Market: NBIX's earnings (37.3% per year) are forecast to grow faster than the US market (14.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NBIX's revenue (21.4% per year) is forecast to grow faster than the US market (7.5% per year).
High Growth Revenue: NBIX's revenue (21.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NBIX's Return on Equity is forecast to be high in 3 years time (32.6%)
Next Steps
Past Performance
How has Neurocrine Biosciences performed over the past 5 years?
14.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NBIX has a large one-off loss of $130.1M impacting its September 30 2019 financial results.
Growing Profit Margin: NBIX's current net profit margins (3.1%) are higher than last year (2.4%).
Past Earnings Growth Analysis
Earnings Trend: NBIX has become profitable over the past 5 years, growing earnings by 14.5% per year.
Accelerating Growth: NBIX's earnings growth over the past year (112.5%) exceeds its 5-year average (14.5% per year).
Earnings vs Industry: NBIX earnings growth over the past year (112.5%) exceeded the Biotechs industry 103.3%.
Return on Equity
High ROE: NBIX's Return on Equity (3.7%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Neurocrine Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: NBIX's short term assets ($819.2M) exceed its short term liabilities ($115.7M).
Long Term Liabilities: NBIX's short term assets ($819.2M) exceed its long term liabilities ($489.8M).
Debt to Equity History and Analysis
Debt Level: NBIX's debt to equity ratio (70.2%) is considered high.
Reducing Debt: Insufficient data to determine if NBIX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: NBIX's debt is well covered by operating cash flow (24.8%).
Interest Coverage: NBIX's interest payments on its debt are well covered by EBIT (11.9x coverage).
Balance Sheet
Inventory Level: NBIX has a low level of unsold assets or inventory.
Debt Coverage by Assets: NBIX's debt is covered by short term assets (assets are 2x debt).
Next Steps
Dividend
What is Neurocrine Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate NBIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NBIX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NBIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NBIX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NBIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Neurocrine Biosciences's salary, the management and board of directors tenure and is there insider trading?
5.3yrs
Average management tenure
CEO
Kevin Gorman (61yo)
12yrs
Tenure
US$8,632,979
Compensation
Dr. Kevin C. Gorman, Ph.D., has been the President and Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008. Dr. Gorman is a Founder of Neurocrine Biosciences, Inc. Dr. Gorman served ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD8.63M) is about average for companies of similar size in the US market ($USD10.76M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Management Age and Tenure
5.3yrs
Average Tenure
54yo
Average Age
Experienced Management: NBIX's management team is seasoned and experienced (5.3 years average tenure).
Board Age and Tenure
10.3yrs
Average Tenure
64yo
Average Age
Experienced Board: NBIX's board of directors are seasoned and experienced ( 10.3 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Kevin Gorman (61yo)
CEO & Director
- Tenure: 12yrs
- Compensation: US$8.63m
Julie Cooke (53yo)
Chief Human Resources Officer
- Tenure: 2.3yrs
Eric Benevich (54yo)
Chief Commercial Officer
- Tenure: 4.7yrs
- Compensation: US$3.67m
Dimitri Grigoriadis (61yo)
Chief Research Officer
- Tenure: 13yrs
- Compensation: US$3.33m
Haig Bozigian (61yo)
Chief Development Officer
- Tenure: 13.1yrs
- Compensation: US$2.97m
Darin Lippoldt (53yo)
Chief Legal Officer & Corporate Secretary
- Tenure: 5.3yrs
Kyle Gano (46yo)
Chief Business Development and Strategy Officer
- Tenure: 9yrs
- Compensation: US$4.57m
Eiry Roberts (55yo)
Chief Medical Officer
- Tenure: 2yrs
- Compensation: US$8.31m
Matt Abernethy (39yo)
Chief Financial Officer
- Tenure: 2.2yrs
- Compensation: US$2.69m
Jane Sorensen
Head of Investor Relations
Board Members
Richard Pops (57yo)
Independent Director
- Tenure: 21.8yrs
- Compensation: US$737.25k
Steve Sherwin (70yo)
Independent Director
- Tenure: 20.8yrs
- Compensation: US$732.58k
Bill Rastetter (71yo)
Independent Chairman of the Board
- Tenure: 8.7yrs
- Compensation: US$873.80k
Gary Lyons (68yo)
Independent Director
- Tenure: 26.9yrs
- Compensation: US$712.75k
Greg Morrow (67yo)
Independent Director
- Tenure: 4.3yrs
- Compensation: US$730.25k
Kevin Gorman (61yo)
CEO & Director
- Tenure: 12yrs
- Compensation: US$8.63m
Leslie Norwalk (54yo)
Director
- Tenure: 0.3yrs
Al Sandrock (61yo)
Independent Director
- Tenure: 4.3yrs
- Compensation: US$733.25k
Company Information
Neurocrine Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Neurocrine Biosciences, Inc.
- Ticker: NBIX
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$9.639b
- Shares outstanding: 92.09m
- Website: https://www.neurocrine.com
Number of Employees
Location
- Neurocrine Biosciences, Inc.
- 12780 El Camino Real
- San Diego
- California
- 92130
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NBIX | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | May 1996 |
| NB3 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 1996 |
| 0K6R | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 1996 |
Biography
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women’s health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company’s product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. also has a research collaboration agreement with Jnana Therapeutics Inc. to discover small molecule therapeutics for central nervous system disorders; a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson’s disease and VY-FXN01 program for Friedreich’s ataxia; and license and collaboration agreement with Xenon Pharmaceuticals Inc. for developing treatments for epilepsy. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/20 23:42 |
| End of Day Share Price | 2020/01/17 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.